Phase II Study of Trilaciclib and Lurbinectidin

People with SCLC are usually treated with a combination of drugs that are approved by the Food and Drug Administration (FDA). However, these drugs may no longer be working in controlling your cancer or may not be a good treatment option for you. This study uses an investigational combination of drugs, trilaciclib and lurbinectedin. The purpose of this study is to test whether trilaciclib helps minimize the side effects of lurbinectedin and therefore improve the safety of lurbinectedin for the treatment of small cell lung cancer (SCLC).